Phase IIa/IIb Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Izalontamab brengitecan (Primary)
- Indications Solid tumours; Urogenital tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 26 Sep 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2027.
- 26 Sep 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 07 May 2025 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.